Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 106 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration 2019:21 de junio. [Ref.ID 103134]
2. Cita con resumen
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]
3. Cita con resumen
Anónimo. Genmab, J&J post data allowing for faster dosing of daratumumab. DIA Daily 2016:5. [Ref.ID 100880]
5.Tiene citas relacionadas Cita con resumen
Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention. an open-label, randomised controlled trial. Lancet 2015;386:2413-21. [Ref.ID 99767]
6.Tiene citas relacionadas Cita con resumen
Garon JR, Orenstein WA. A worldwide shift in polio vaccines for routine immunisation. Lancet 2015;386:2375-7. [Ref.ID 99752]
7. Cita con resumen
Maurice J. And then there were two…polio-endemic countries. Lancet 2015;386:1521-2. [Ref.ID 99659]
8. Cita con resumen
Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet 2015;386:376-87. [Ref.ID 99368]
9. Cita con resumen
Pi-Sunyer X, Astrup A, Fuijoka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Ortiz RV, Jensen CB, Wilding JPH, for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. [Ref.ID 99228]
10. Cita con resumen
Scholten W. Paediatric morphine dosages. WHO Pharmaceuticals Newsletter 2012;4:26-8. [Ref.ID 93684]
11. Cita con resumen
Anónimo. Extended-release exenatide (Bydureon) for type 2 diabetes. Med Lett Drugs Ther 2012;54:21-3. [Ref.ID 92604]
12. Cita con resumen
Anónimo. Deferiprone (Ferriprox) for iron overload. Med Lett Drugs Ther 2012;54:15-6. [Ref.ID 92429]
13. Cita con resumen
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Cost-effectiveness of disease-modifying therapy for multiple sclerosis. A population-based study. Neurology 2011;77:355-63. [Ref.ID 90812]
14.Tiene citas relacionadas Cita con resumen
Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, Kollman C, Nodale M, Murphy HR, Dunger DB, Amiel SA, Heller SR, Willinska ME, Evans ML. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:906. [Ref.ID 90482]
15.Tiene citas relacionadas Cita con resumen
Kovatchev B. Closed loop control for type 1 diabetes. BMJ 2011;342:883-4. [Ref.ID 90474]
16.Tiene citas relacionadas Cita con resumen
Yudkin JS, Lehman R, Krumholz HM. Glucagon-like peptide-1 drugs. Use of GLP-1 analogues needs great caution. BMJ 2011;342:563. [Ref.ID 90292]
17.Enlace a cita original
Mengiardi S, Tsakiris DA, Lampert ML, Hersberger KE. Drug use problems with self-injected low-molecular-weight heparins in primary care. Eur J Clin Pharmacol 2011;67:109-20. [Ref.ID 90125]
18. Cita con resumen
Anónimo. Denosumab (Prolia) for postmenopausal osteoporosis. Med Lett Drugs Ther 2010;52:81-2. [Ref.ID 89521]
19.Tiene citas relacionadas
Diamant M, on behalf of the DURATION-3 investigators. Exenatide in type 2 diabetes. Authors' reply. Lancet 2010;376:1053. [Ref.ID 89423]
20.Tiene citas relacionadas
Verzegnassi F, Chinello M. Exenatide in type 2 diabetes. Lancet 2010;376:1052-3. [Ref.ID 89422]
Seleccionar todas
 
 1 a 20 de 106 siguiente >>